Attending physician, at The Affiliated Hospital of Qingdao University, China.

Dr. Xianjuan Zhang is a rising virologist and clinical researcher at the Department of Clinical Laboratory, the Affiliated Hospital of Qingdao University. She earned her Ph.D. and M.Sc. in Pathogen Biology from Qingdao University, dedicating her academic career to investigating the pathogenic mechanisms of Human Cytomegalovirus (HCMV). With a strong foundation in virology, molecular biology, and immune evasion strategies, she has published impactful studies in top-tier journals, including Cellular and Molecular Gastroenterology and Hepatology, PLoS One, and Molecular Neurobiology. Dr. Zhang’s work provides novel insights into virus-host interactions and opens avenues for potential therapeutic interventions. Her research excellence is matched by her dedication to academic service as a peer reviewer for the International Journal of Molecular Sciences. With a strong command of advanced laboratory and bioinformatics tools, Dr. Zhang continues to contribute significantly to the understanding of viral pathogenesis. 📖🧫🔍

Professional Profile

Scopus

🎓 Education

Dr. Xianjuan Zhang pursued both her doctoral and master’s degrees in Pathogen Biology at Qingdao University, China. During her M.Sc. (2016–2019), she developed a strong grasp of virology and immunology fundamentals, laying the groundwork for her more advanced research pursuits. Her Ph.D. studies (2019–2023) were marked by in-depth exploration of Human Cytomegalovirus (HCMV) and its impact on host cells, where she utilized in vivo and in vitro models to unravel molecular and immunological interactions. She mastered a wide range of technical tools including CRISPR, qPCR, siRNA knockdown, Western blotting, and bioinformatics analysis, which enabled her to investigate virus-host mechanisms at a molecular level. Her academic journey reflects not only deep theoretical understanding but also a practical orientation toward translational virology research. Her graduate education laid the foundation for a promising research career focused on infection, immunity, and molecular pathogenesis. 🎓🧪📘

🧑‍🔬 Experience

Dr. Zhang has amassed valuable academic and professional experience centered on virology and molecular biology. Since 2023, she has served as a peer reviewer for the International Journal of Molecular Sciences, where she evaluates cutting-edge research on host-pathogen interactions, immune modulation, and therapeutic strategies. This role reflects her standing in the scientific community and her expertise in viral pathogenesis. In her research role at the Affiliated Hospital of Qingdao University, Dr. Zhang contributes to multidisciplinary projects aimed at understanding the cellular impact of Human Cytomegalovirus. She collaborates with pathologists, microbiologists, and molecular biologists, enhancing both the quality and translational potential of her research. Her work spans embryonic development, immune suppression, and metabolic syndromes linked to viral infections. Dr. Zhang’s collaborative and peer-reviewed experience demonstrates her capability to contribute both as a researcher and a reviewer in high-impact scientific contexts. 🧬🧫👩‍⚕️

🔬 Research Interests

Dr. Zhang’s research revolves around the complex interplay between viruses and their hosts, with a primary focus on Human Cytomegalovirus (HCMV). Her studies explore how HCMV modulates host immune systems through evasion mechanisms, particularly focusing on the IL10/STAT3 pathway and antigen presentation suppression in macrophages. She is interested in decoding the molecular mechanisms by which viral proteins interfere with embryonic development, hepatic functions, and neurogenesis, using transgenic mouse models. In addition, Dr. Zhang investigates the role of the gut microbiome and viral infections in metabolic diseases such as hepatic steatosis and gestational diabetes. Her work seeks to identify novel therapeutic targets and enhance understanding of virus-induced pathologies. By leveraging molecular biology, immunological assays, and bioinformatics, Dr. Zhang’s research aims to bridge laboratory findings with clinical applications, offering potential advancements in diagnostics and treatment strategies for viral infections. 🦠🧠💉

🏅 Awards

Dr. Xianjuan Zhang is a nominee for excellence in early-career virology research due to her impactful studies and commitment to scientific advancement. Although still in the early stages of her professional journey, her work has been published in high-impact journals and widely cited by the virology research community. Her contributions to understanding the effects of HCMV on organ development and immune regulation have positioned her as a promising voice in the field. She has been actively engaged in academic service through peer review, demonstrating leadership and responsibility in maintaining scientific integrity. Her nominations stem from both research merit and her application of science to solve critical health issues. With a portfolio of interdisciplinary studies connecting virology, immunology, and metabolic health, Dr. Zhang is a compelling candidate for any early-career research excellence awards. 🏆📚🧪

📚 Top Noted Publications

Dr. Zhang has authored and co-authored several impactful research papers on Human Cytomegalovirus and its pathological mechanisms. Her publication record demonstrates a consistent focus on viral interference with host systems:

1. Zhang X., et al. (2022)

Title: Human Cytomegalovirus-IE2 Affects Embryonic Liver Development and Survival in Transgenic Mouse
Journal: Cellular and Molecular Gastroenterology and Hepatology
Volume: 14(2), Pages: 494–511
DOI: 10.1016/j.jcmgh.2022.01.002
Cited by: 14
Summary: This study investigates the effects of the human cytomegalovirus (HCMV) immediate-early protein 2 (IE2) on embryonic liver development. Using a transgenic mouse model, the researchers demonstrate that IE2 impairs hepatic development, leading to increased embryonic mortality, likely due to disrupted hepatocyte differentiation and survival mechanisms.

2. Zhang X., et al. (2025)

Title: HCMV-IE2 suppresses antigen presentation via IL10/STAT3 pathway
Journal: PLoS One
Volume: 20(5), Article ID: e0322334
DOI: 10.1371/journal.pone.0322334
Cited by: 3
Summary: This paper describes how HCMV-IE2 modulates host immune responses. Specifically, it shows that IE2 inhibits antigen presentation by upregulating IL-10 and activating the STAT3 signaling pathway, leading to immune evasion. This mechanism could contribute to persistent infection and immune suppression.

3. Niu D., Zhang X., et al. (2023)

Title: IE2 disrupts neural progenitor development
Journal: Molecular Neurobiology
Volume: 60(7), Pages: 3883–3897
DOI: 10.1007/s12035-023-03348-2
Cited by: 5
Summary: This study explores the neurodevelopmental impact of HCMV-IE2, showing that IE2 expression disrupts neural progenitor cell proliferation and differentiation. The findings suggest a molecular basis for HCMV-related neurodevelopmental disorders in congenital infections.

4. Zhou X., Zhang X., et al. (2023)

Title: Gut microbiota induces hepatic steatosis
Journal: Scientific Reports
Volume: 13(1), Article ID: 6701
DOI: 10.1038/s41598-023-33829-4
Cited by: 8
Summary: This article investigates the role of gut microbiota in liver fat accumulation. It finds that alterations in microbial composition can induce hepatic steatosis in mice, potentially via modulation of metabolic and inflammatory pathways. Zhang X.’s contribution adds insights into host-microbiome interactions and liver health.

5. Wang Y., Zhang X., et al. (2022)

Title: HCMV and gestational diabetes
Journal: PeerJ
Volume: 10, Article ID: e1293
DOI: 10.7717/peerj.1293
Cited by: 6
Summary: This study explores the association between HCMV infection and gestational diabetes mellitus (GDM). The authors suggest a potential link between HCMV-induced immune dysregulation and glucose intolerance during pregnancy, providing new insight into viral contributions to metabolic disorders.

Conclusion

Dr. Xianjuan Zhang is a promising early-career researcher whose focused contributions to HCMV pathogenesis and host interactions are impactful and published in high-quality journals. Her technical capabilities, publication record, and reviewer role indicate a high level of scientific maturity for her career stage.

Xuemin Jin | Medical Hypotheses | Best Researcher Award

Posted on 24/05/202524/05/2025 by ScienceFather

Xuemin Jin | Medical Hypotheses | Best Researcher Award

Assoc. Prof. Dr Xuemin Jin, Jilin University, China

Assoc. Prof. Dr. Xuemin Jin is a leading scientist in the field of veterinary parasitology and zoonotic diseases. With over a decade of research experience, she has contributed significantly to understanding host–parasite–microbiome interactions, helminth immunology, and vaccine development. Currently an Associate Professor at the Institute of Zoonoses, Jilin University, she holds key roles in national and international scientific bodies, such as the International Commission on Trichinosis and the OIE Collaborating Centre for Foodborne Parasitic Diseases. Her work bridges parasitology, microbiota, and immunology, with her findings published in high-impact journals like Signal Transduction and Targeted Therapy, Gut Microbes, and PLoS Pathogens. A recipient of several prestigious grants from China’s National Natural Science Foundation and the Ministry of Science and Technology, Dr. Jin is a recognized leader advancing the frontiers of zoonotic parasitic disease research.

Publication Profile

Orcid

Education

Dr. Xuemin Jin completed her academic training entirely at Jilin University, one of China’s top veterinary and medical research institutions. She earned her Bachelor of Science (B.S.) in Veterinary Medicine from the College of Veterinary Medicine in 2015. She then pursued a Ph.D. in Veterinary Parasitology, completed in 2020, where she explored the molecular and immunological mechanisms of Trichinella spiralis. Following her doctorate, she continued her scholarly path as a Postdoctoral Fellow from 2020 to 2022 at the Institute of Zoonoses, Jilin University, where she specialized in zoonotic parasitic infections and host-pathogen interactions. Her academic trajectory showcases a strong foundation in experimental parasitology, immunomodulation, and zoonotic disease control strategies.

Experience

Dr. Jin began her academic career as a Lecturer at the College of Veterinary Medicine, Jilin University (2020–2022), contributing to teaching and mentoring in parasitology and immunopathology. Since 2022, she has been serving as an Associate Professor at the Institute of Zoonoses, where she leads research on Trichinella spiralis and intestinal helminth-microbiota interactions. She plays a key role in collaborative vaccine development initiatives and oversees multiple research grants. Additionally, she has held notable academic positions including committee memberships in the 8th Veterinary Discipline Evaluation Group of the State Council, OIE Collaborating Centre, and the International Commission on Trichinosis. These roles highlight her credibility and thought leadership in the field.

Awards and Honors

Dr. Jin has received multiple accolades through prestigious national-level funding, including leading and sub-leading roles in National Natural Science Foundation of China’s Key Program and 14th Five-Year Plan Key R&D Projects by the Ministry of Science and Technology. These grants, totaling millions of RMB, underscore the scientific community’s trust in her expertise. She serves as a Committee Member for global parasitology initiatives such as the International Commission on Trichinosis, and holds national recognition through the Veterinary Discipline Evaluation Group of the Academic Degrees Committee of the State Council. Her continuous engagement in international and policy-level scientific networks highlights her influential status in zoonotic and veterinary research.

Research Focus

Dr. Jin’s primary research centers on zoonotic parasitic diseases, particularly Trichinella spiralis, integrating host immunity, microbiome regulation, and vaccine development. Her work reveals novel immunological mechanisms, such as the role of β-glucans and intestinal bacteria (e.g., Akkermansia muciniphila) in modulating helminth-induced pathology and immune responses. She has made groundbreaking findings in TLR2/NLRP3-mediated pathways, host-protective immunity, and the cross-talk between helminths and commensal gut bacteria. Additionally, she contributes to the development of recombinant and genetically engineered vaccines for zoonotic infections, aligning with global One Health strategies. Her research is interdisciplinary, with applications in veterinary public health, immunology, and parasitic disease control.

Publication Top Notes

The effect of β-Glucan induced intestinal trained immunity against Trichinella spiralis infection.

Trichinella spiralis alleviates LPS-induced acute lung injury by modulating the protective Th2 immune response.

Helminth alleviates COVID-19-related cytokine storm in an IL-9-dependent way.

Yeast β-glucan promotes antiviral type I interferon response via dectin-1.

Trichinella spiralis excretory/secretory products from adult worms inhibit NETosis and regulate the production of cytokines from neutrophils.

Akkermansia muciniphila participates in the host protection against helminth-induced cardiac fibrosis via TLR2.

In vitro knockdown of TsDNase II-7 suppresses Trichinella spiralis invasion into the host’s intestinal epithelial cells.

ALI KAISSI | Medicine and Health Sciences | Excellence in Research Award

Posted on 07/05/202507/05/2025 by ScienceFather

ALI KAISSI | Medicine and Health Sciences | Excellence in Research Award

Prof. Dr ALI KAISSI, orthopaedic Hospital Speising Vienna, Austria

Dr. Ali Al Kaissi is a distinguished medical scientist and consultant in pediatric orthopedics with an illustrious international career spanning over four decades. A graduate of Al-Azhar University, Cairo, he pursued postgraduate training and specialization in the United Kingdom, Tunisia, Austria, and Russia. He is best known for his groundbreaking contributions to pediatric skeletal dysplasias and genetic disorders, including the identification of Al Kaissi syndrome (OMIM 617694). As an honorary professor and senior researcher, he has collaborated with prestigious institutions such as the Turner Orthopedic Institute (Russia), Ilizarov Institute (Kurgan), and the University of Saskatchewan (Canada). Dr. Al Kaissi’s multidisciplinary expertise and diagnostic acumen have contributed to the understanding of complex orthopedic and craniofacial disorders. His global impact is reflected through his numerous publications, awards, and honorary appointments.

Publication Profile

Scopus

Education

Dr. Al Kaissi received his foundational medical degree from Al-Azhar University, Cairo (1978). He continued his postgraduate education in the United Kingdom, earning a Certificate in Pediatrics (1988), followed by a Master’s degree in Pediatric Developmental Abnormalities from the University of Warwick (1990). His academic excellence was later recognized with a Doctor of Science (Honorary) from the Turner Scientific Research Institute for Children’s Orthopedics in Saint Petersburg, Russia (2017). His educational path reveals a strong emphasis on pediatric orthopedics, developmental abnormalities, and rare syndromic disorders. His continuous pursuit of medical education, coupled with his pioneering research, has laid the foundation for significant clinical contributions and novel diagnostic insights into congenital and acquired musculoskeletal diseases.

Experience

Dr. Al Kaissi has held numerous high-level clinical and research positions internationally. Since 2005, he has served as a consultant and scientist at the Orthopedic Hospital of Speising in Vienna, Austria. Previously, he led pediatric orthopedic clinical research at the Children’s Hospital in Tunis, Tunisia (1993–2005), where he also established a national center for early recognition of congenital malformation complexes. He has been involved in key medical posts in Iraq, the UK, and Russia, spanning from senior house officer roles to visiting professorships. His experience encompasses both the clinical management of pediatric orthopedic conditions and pioneering research into rare skeletal dysplasias and syndromes. His extensive global collaborations and ability to identify novel pathologies have positioned him as a leader in diagnostic orthopedic research.

Awards and Honors

Dr. Al Kaissi has been the recipient of numerous international awards recognizing his excellence in clinical research and diagnostics. He received the prestigious Russian Golden Medal for Distinguished Clinicians and the Silver Dagestani Sword in 2019. In 2017, he was conferred an Honorary Doctorate (DSc) from the Turner Pediatric Orthopedic Institute, Russia. His contributions have been acknowledged by ministries of health in Russia and Tunisia, among others. He holds honorary professorships at premier Russian institutions including the Ilizarov Institute and the Pediatric Kidney Clinic of Dagestan. His honors reflect not only individual achievement but also the broader impact of his diagnostic innovations on pediatric care and genetic research.

Research Focus

Dr. Al Kaissi’s research focuses on pediatric skeletal dysplasias, craniofacial anomalies, syndromic disorders, and orthopedic genetics. He has discovered and characterized several new syndromes including “Al Kaissi syndrome” (OMIM 617694) and contributed to the understanding of 3MC syndrome and Desbuquois dysplasia-like conditions. His diagnostic insights into wormian bones and thoracic collapse disorders have redefined clinical approaches in developmental orthopedics. His collaboration with environmental scientists has broadened his scope to ecotoxicology and skeletal pathology in wildlife exposed to toxins, reflecting a unique intersection between human and environmental health. His publications cover radiographic and tomographic evaluations, syndrome delineation, and the interplay of environmental exposures with skeletal disease. His work continues to shape diagnostic criteria and management protocols globally.

Publication Top Notes

Al Kaissi Syndrome – OMIM (617694): Identified a novel syndrome with growth retardation, spinal malformation, and dysmorphic facies.
3MC Syndrome with Baraitser – OMIM (257920): Defined craniofacial and skeletal anomalies in conjunction with Michael Baraitser.
“Progressive Collapse of the Thoracic Cage” – American Journal of Medicine, 2017.
“Novel Conception of Wormian Bones” – Diagnostics Journal, 2023.
“Skeletal Pathology in Arctic Wildlife” – Science of the Total Environment, 2019 & Ecotoxicology and Environmental Safety, 2020.
“Meticulous and Early Understanding of Cranial Defects Can Save Lives” – Children, 2023.
“Craniofacial Malformations in Syndromic Entities” – Diagnostics, 2022.
“Arthrogryposis and Escobar Syndrome” – Minerva Pediatrics, 2024.
“Non-lethal ZMPSTE24 Mutation in Progeria” – Clinical Genetics, 2023.

Mohamed Hassan | Medicine and Health Sciences | Best Researcher Award

Posted on 15/03/202515/03/2025 by ScienceFather

Mohamed Hassan | Medicine and Health Sciences | Best Researcher Award

Assist. Prof. Dr Mohamed Hassan, Tulane University School of Medicine, United States

Assist. Prof. Dr. Mohamed Hassan is a distinguished researcher in molecular biology, tumor biology, and virology 🧬. His groundbreaking work focuses on tumor progression, cancer stem cell biology, and innovative therapeutic strategies 🎯. With an extensive portfolio of high-impact publications 📄 and supervised doctoral candidates 🎓, his research significantly contributes to understanding melanoma resistance, non-receptor tyrosine kinases, and immune checkpoint inhibitors 🏥. He has collaborated with leading international institutions, enriching the field with novel discoveries in oncology 🔬. His contributions extend beyond research, fostering the next generation of scientists and improving clinical oncology outcomes 🏥.

Publication Profile

Orcid

Education

Dr. Mohamed Hassan earned his Ph.D. in Molecular Biology 🏅 from the University Hospital of Düsseldorf, Germany (2001), where his research focused on the interference of the Hepatitis C Virus (HCV) core protein with intracellular signal transduction in liver cells 🦠. He holds an M.Sc. in Molecular Biology 📖 from the University of Düsseldorf (1996), with a thesis on identifying and characterizing differentially expressed cDNA libraries in Plasmodium malaria chabaudi immune mice 🧪. His academic journey began with a B.Sc. in Biological Sciences 🏫 from Zagazig University, Egypt, and the University of Düsseldorf (1983). His expertise in cancer biology, virology, and molecular research 📊 has established him as a leading researcher in the field.

Experience

Assist. Prof. Dr. Mohamed Hassan is a dedicated cancer researcher with extensive expertise in tumor progression, oncological drug resistance, and precision medicine 🔬💊. He is currently a Senior Postdoctoral Fellow at the Institut National de la Santé et de la Recherche Médicale, University of Strasbourg, France (2018-2025) 🏥. Previously, he served as a Research Assistant Professor at Tulane University School of Medicine, USA (2016-2018) 🎓, and a Postdoctoral Fellow at the University Hospital of Düsseldorf, Germany (2002-2004). His groundbreaking work focuses on identifying biomarkers and developing targeted therapies to enhance cancer treatment worldwide 🌍🧬.

Research Focus

Assist. Prof. Dr. Mohamed Hassan’s research focuses on tumor progression, cancer stem-like cells, and treatment resistance 🧬. His work delves into melanoma’s resistance to standard therapies 🎯, mechanisms of tumor progression and immune evasion 🏥, and targeting cancer stem-like cells to enhance treatment efficacy 💊. He investigates the role of non-receptor tyrosine kinases in oncogenesis 🔬 and explores immune checkpoint inhibitors and their associated cutaneous adverse effects ⚕️. Additionally, his discovery of antimicrobial peptides holds promise for clinical applications 🦠. His contributions drive novel therapeutic strategies, improving cancer treatment outcomes worldwide 🌍.

Publication Top Notes

Reduction of Prostate Cancer Risk: Role of Frequent Ejaculation-Associated Mechanisms

Immune Checkpoint Inhibitor-Associated Cutaneous Adverse Events: Mechanisms of Occurrence

Non-Receptor Tyrosine Kinases: Their Structure and Mechanistic Role in Tumor Progression and Resistance

<i>hTERT</i> Epigenetics Provides New Perspectives for Diagnosis and Evidence-Based Guidance of Chemotherapy in Cancer

CD133-Dependent Activation of Phosphoinositide 3-Kinase /AKT/Mammalian Target of Rapamycin Signaling in Melanoma Progression and Drug Resistance

Mechanisms of Melanoma Progression and Treatment Resistance: Role of Cancer Stem-like Cells

Induction of Antimicrobial Protein S100A15 Expression by Oral Microbial Pathogens Is Toll-like Receptors-Dependent Activation of c-Jun-N-Terminal Kinase (JNK), p38, and NF-κB Pathways

Jonathan Trent | Medicine and Health Sciences | Lifetime achievement Award

Posted on 13/03/202513/03/2025 by ScienceFather

Jonathan Trent | Medicine and Health Sciences | Lifetime achievement Award

Prof. Dr Jonathan Trent, Sylvester Comprehensive Cancer Center, University of Miami, United States

Prof. Dr. Jonathan Trent is a distinguished oncologist and researcher, specializing in sarcoma and precision medicine. With an MD and PhD from The University of Texas Health Science Center, he has dedicated his career to advancing cancer treatment. As Associate Director of Clinical Research at Sylvester Comprehensive Cancer Center, he leads groundbreaking studies in medical oncology. His leadership in precision medicine has transformed sarcoma treatment strategies. A prolific author, he has contributed to numerous high-impact publications, shaping the future of cancer therapy. Recognized for his mentorship and excellence in patient care, he has received prestigious awards like Sylvester Outstanding Mentor of the Year. His commitment to clinical innovation and translational research continues to impact oncology worldwide.

Publication Profile

Scopus

Education

Prof. Dr. Jonathan Trent earned his BS in 1988 from Southeastern Oklahoma State University, Durant, OK. He then pursued an MD-PhD program at The University of Texas Health Science Center, Houston, TX (1988-1995), where he developed expertise in oncology and medical research. His postgraduate training includes a Clinical Internship (1995-1996) and a Clinical Residency (1997-1999) at the same institution. He further specialized in cancer treatment through a Medical Oncology Fellowship at MD Anderson Cancer Center (1999-2002), where he also served as Chief Fellow. His extensive academic training laid a strong foundation for his groundbreaking research in sarcoma and precision medicine.

Experience

Prof. Dr. Jonathan Trent began his academic career as Assistant Professor (2002-2008) and later Associate Professor (2008-2011) at MD Anderson Cancer Center. He also served as an Adjunct Professor (2014-2015) at its Graduate School of Biomedical Sciences. Since 2013, he has been a Professor of Medicine at the University of Miami, where he is also Associate Director of Clinical Research, Director of the Sarcoma Medical Research Program, and Director of Precision Medicine at Sylvester Comprehensive Cancer Center. His leadership in sarcoma research, clinical trials, and precision oncology has significantly advanced cancer treatment.

Awards and Honors

Prof. Dr. Jonathan Trent has received numerous prestigious awards for his contributions to oncology, including the Sylvester Outstanding Mentor of the Year 🏆 (Miller School of Medicine, 2015), the Outstanding Care Award 🏅 (Sarcoma Alliance, 2012), and the Leadership in Clinical Research 🎖️ (Sylvester Comprehensive Cancer Center). He is an esteemed member of elite professional organizations such as the American Society for Clinical Oncology (ASCO), the American Association of Cancer Research (AACR), and The Max Foundation. His dedication to oncology research and patient care has earned him national and international recognition.

Research Focus

Prof. Dr. Jonathan Trent’s research focuses on sarcoma, targeted therapies, and precision oncology. He has played a pivotal role in the development of novel therapies, including TRK fusion inhibitors, CDK7-targeted treatments, and IDH1 mutation-based interventions. His work has significantly improved the understanding of leiomyosarcoma, chondrosarcoma, and desmoid tumors. As Director of Sarcoma Medical Research and Precision Medicine at Sylvester Comprehensive Cancer Center, he integrates genomic profiling and personalized treatment strategies to enhance patient outcomes. His extensive clinical trials and translational research have shaped modern sarcoma therapies, contributing to groundbreaking advancements in oncology.

Publication Top Notes

A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors

Gastrointestinal Stromal Tumor Patients with Molecular Testing Exhibit Superior Survival Compared to Patients without Testing: Results from the Life Raft Group (LRG) Registry

Beyond the Driver Mutation: Immunotherapies in Gastrointestinal Stromal Tumors

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA

Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours

Use of tyrosine kinase inhibitors in patients with GI stromal tumor who are pregnant or considering pregnancy: Driver mutations and circulating tumor DNA

Limb-sparing surgery plus radiotherapy results in superior survival: an analysis of patients with high-grade, extremity soft-tissue sarcoma from the NCDB and SEER

GORDON WEST | Medicine and Health Sciences | Best Researcher Award

Posted on 24/02/202524/02/2025 by ScienceFather

GORDON WEST | Medicine and Health Sciences | Best Researcher Award

Dr GORDON WEST, Pacific Lutheran University School of Nursing – Tacoma, WA, United States

Dr. Gordon West is a dedicated nurse scientist and healthcare leader with a PhD from the Uniformed Services University (2016) 🎓. He holds an MHA from Baylor University (2006) and a BSN from McMurry University (1998) 🏥. Currently, he is a Research Nurse at The Geneva Foundation-Madigan and an Assistant Professor at Pacific Lutheran University 📚. With vast experience in military and civilian healthcare, he has led numerous research projects on infection control, patient safety, and military health 🩺. A Fellow of the American College of Healthcare Executives, he has received multiple awards for nursing research and excellence 🏆.

Publication Profile

Google Scholar

Education

Dr. Gordon West 🎓 is a dedicated healthcare professional with a strong academic background. He earned his Ph.D. in 2016 from the Uniformed Services University of the Health Sciences 🏥 in Bethesda, MD. Prior to that, he completed his Master of Healthcare Administration (MHA) in 2006 at Baylor University 🏛️ in Fort Sam Houston. His journey in healthcare began with a Bachelor of Science in Nursing (BSN) from McMurry University 🎓 in Abilene, TX, in 1998. With extensive education and expertise, Dr. West continues to contribute to the field of healthcare and administration with passion and dedication. 💉📚

Experience

Dr. Gordon West is a dedicated Research Nurse 🩺 at The Geneva Foundation – Madigan (2023-present) and an Assistant Professor 📚 at Pacific Lutheran University (2022-present). He actively contributes as a Research Board Member at the Washington State Nursing Association & Health Care Council and a Board Member at Rainer Olympic Nurses Association. His extensive military nursing career includes leadership roles at Madigan AMC, Tripler, and Fort Belvoir 🏥, alongside international service in Korea 🇰🇷 and Iraq 🇮🇶. A Ph.D. graduate from USUHS 🎓, he also teaches at Maryville University and Central Michigan University, shaping future nursing professionals. 🌟

Awards & Honors

Dr. Gordon West has been recognized for his outstanding contributions to nursing and healthcare research 🏥📚. In 2023, he received a Daisy Nomination from Pacific Lutheran University for his dedication to patient care and nursing excellence 🌿🏆. In 2019, he was honored with the ANCA Nursing Research Award by the Army Nurse Corps Association, highlighting his impactful research in military nursing 🎖️🔬. That same year, he also received the Excellence in Nursing Research Award from the Defense Health Agency, acknowledging his commitment to advancing healthcare through evidence-based practices and innovation 🏅💡.

Research Focus

Dr. Gordon B. West’s research explores critical language pedagogy 🎓📖, focusing on morality, identity, and power in neoliberal English language education 🌍💬. His work critically examines good teacher identities in South Korea 🇰🇷, the politicization of language educators 🗣️⚖️, and the emotional complexities of critical pedagogy ❤️🧠. He also investigates sociohistorical perspectives on literacy 📚⏳ and the challenges of critical practitioner research under difficult conditions 🔍🛠️. Through qualitative and materialist approaches, Dr. West sheds light on language education as both a tool for liberation and oppression ✊🔗, emphasizing the impact of neoliberalism on English teaching 💵🏫.

Presentation

Dr. Gordon West is a dedicated nursing researcher focusing on infection control 🦠, patient safety 🏥, and healthcare communication 📢. He has presented extensively, including at the Phyllis J. Verhonick Conference (2016) on patient education and fall prevention 🩺. His work on bacterial contamination of hospital uniforms led to multiple presentations at the American Organization of Nurse Executives Conference (2016-2017) and the Sigma 29th International Nursing Research Conference in Melbourne (2018) 🌏. He also explored hands-free communication in nursing at TSNRP (2017). His research enhances clinical safety, infection prevention, and nurse satisfaction, shaping better healthcare practices globally 🌍.